Kodiak Sciences Inc.
KODHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Kodiak Sciences Inc. (KOD) is listed under Biotechnology. The $2.30B market capitalization puts KOD squarely in mid-cap range for its industry. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Market Cap
$2.30B
Beta
2.32
P/E (TTM)
—
P/E (Fwd)
-11.78
EPS (TTM)
$-4.17
EPS (Fwd)
$-3.12
ROE
-208.8%
ROA
-49.1%
Cash
$169.5M
Total Debt
$56.0M
Free CF
-$52.2M
52W Change
919.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $169.5M in cash comfortably exceeding the $56.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$52.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -208.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Kodiak Sciences Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kodiak Sciences Inc.'s trajectory.